INO
NASD Inovio Pharmaceuticals, Inc.$1.17 ↑ +0.01 (+1.26%) Trading Up from the previous close of $1.16, $0.02 below the day’s high of $1.19
- YTD change
- -32.78%
- vs 20-day SMA
- -2.98%
- vs 200-day SMA
- -12.99%
Price ranges
Price & Performance
+0.08 (+7.62%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.7% away from all-time highs of $405.48
- INO is down 33% since the beginning of the year
- INO is down 51% over the past 12 months
- INO is down 18% over the past 1 month
- 19% of all INO investors are betting against INO
INO reads neutral: price sits below both the 20- and 200-day averages, the 12-month move is -52.7%.
- Previous minute
- +$0.01
- Last hour
- +$0.01
- Last 5 days
- +5.37%
- vs 8-day SMA
- +0.29%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
